Article: Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.
The Journal of infectious diseases
2007 Volume 195, Issue 10, Page(s) 1489–1496
Abstract: Background: The effect of anti-tumor necrosis factor (TNF)-alpha treatment in Borrelia burgdorferi-infected and ceftriaxone-treated C3H/He mice was evaluated.: Methods: Mice were infected with B. garinii A218 or B. burgdorferi sensu stricto N40. At 2 ...
Abstract | Background: The effect of anti-tumor necrosis factor (TNF)-alpha treatment in Borrelia burgdorferi-infected and ceftriaxone-treated C3H/He mice was evaluated. Methods: Mice were infected with B. garinii A218 or B. burgdorferi sensu stricto N40. At 2 weeks of infection, one group was treated simultaneously with ceftriaxone and anti-TNF-alpha, whereas another received ceftriaxone at 2 weeks and anti-TNF-alpha 4 weeks later. One group received ceftriaxone treatment only. Infected and noninfected control groups were sham treated. Results: At 14 weeks of infection, B. burgdorferi could not be detected by cultivation or by polymerase chain reaction in tissue samples of any mouse treated with ceftriaxone only. However, spirochetes grew from the tissue samples of one-third of the mice treated with anti-TNF-alpha simultaneously or 4 weeks after ceftriaxone. These activated spirochetes showed ceftriaxone sensitivity rates, plasmid profiles, and virulence rates similar to those of bacteria used to infect the mice. All infected control mice and mice given anti-TNF-alpha only were culture positive. Conclusions: This report shows that, after ceftriaxone treatment for 5 days, a portion of B. burgdorferi-infected mice still have live spirochetes in their body, which are activated by anti-TNF-alpha treatment. |
---|---|
MeSH term(s) | Animals ; Anti-Bacterial Agents/therapeutic use ; Antibodies/therapeutic use ; Borrelia burgdorferi/drug effects ; Borrelia burgdorferi/pathogenicity ; Borrelia burgdorferi/physiology ; Borrelia burgdorferi Group/drug effects ; Borrelia burgdorferi Group/isolation & purification ; Ceftriaxone/adverse effects ; Ceftriaxone/therapeutic use ; Disease Models, Animal ; Immunoglobulin G/therapeutic use ; Joint Diseases/chemically induced ; Joint Diseases/prevention & control ; Kinetics ; Lyme Disease/drug therapy ; Mice ; Mice, Inbred C3H ; Rats ; Spirochaetales/drug effects ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology |
Chemical Substances | Anti-Bacterial Agents ; Antibodies ; Immunoglobulin G ; Tumor Necrosis Factor-alpha ; Ceftriaxone (75J73V1629) |
Language | English |
Publishing date | 2007-05-15 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3019-3 |
ISSN | 1537-6613 ; 0022-1899 |
ISSN (online) | 1537-6613 |
ISSN | 0022-1899 |
DOI | 10.1086/513873 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uh II Zs.50: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 445: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.